BICX - BioCorRx wins revised notice of award to extend NIDA grant for naltrexone implant development

BioCorRx (BICX) has received a revised notice of award ((NoA)) to extend the current UG3 phase of the grant awarded by the National Institute on Drug Abuse ((NIDA)), part of the National Institutes of Health ((NIH)).The grant was awarded to support the advancement of a sustained release naltrexone implant for the treatment of opioid and alcohol use disorders being developed by BioCorRx’s subsidiary, BioCorRx Pharma.This notice of award revision gives the company more time to get its IND application finalised and submitted to the FDA, it said.The company reiterated that it relies heavily on third parties to complete its application, which could lead to further delays.

For further details see:

BioCorRx wins revised notice of award to extend NIDA grant for naltrexone implant development